Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
Date:11/27/2007

CALGARY, Nov. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia." The claims describe methods of using the reovirus to treat cancers that have inactivated PKR, whether the PKR is inactivated by mutation of Ras or by other factors. PKR is a host cellular protein responsible for preventing virus replication within a cell. Tumour cells lacking the activity of PKR are susceptible to reovirus replication and subsequently, cancer cell killing.

"This patent represents a significant expansion of our intellectual property portfolio," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The claims cover additional pathways whereby tumours can become susceptible to reovirus infection and cell death."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 Ale Gicqueau, Founder and ... of Clinical Affairs at Align Technology, on “ Conducting ... upcoming ACRP 2015 Global Conference and Exhibition on April ... , During the poster presentation, Ale Gicqueau and ... running a Postmarket Registry, the requirements and resources to ...
(Date:3/25/2015)... ROCKVILLE, Md. , March 25, 2015 ... for the Vaccine Industry Excellence (ViE) Award "Best Clinical ... second consecutive year that Optimal has been selected as ... World Vaccine Congress, receiving a "Highly Recommended" distinction in ... generate recognition of the efforts, accomplishments, and positive contributions ...
(Date:3/25/2015)... and REYKJAVIK, Iceland , March 25, ... using the genome to create better medicine, today congratulated the ... studies of whole-genome data yet undertaken. The ... – are built around the most comprehensive population-wide ... of deCODE scientists led by Kari Stefansson , deCODE,s ...
(Date:3/25/2015)... MN (PRWEB) March 25, 2015 ... breakthrough in nanoparticle technology that will enable broader ... many other diseases with a simple breath screen. ... on the U.S. Food and Drug Administration (FDA) ... launch of the innovative Nanoparticle Biomarker Tagging device. ...
Breaking Biology Technology:Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... - The technological march has added so much complexity ... its promised benefits. , ,That according to John Swainson, ... delivered the opening keynote address at the 2007 ... to help bridge the relationship between business and information ...
... Wis. - The prospect of e-discovery and the possibility - ... any chief executive reach for antacids, but if the CEO's top ... of heartburn can be avoided. , ,That was the message of ... Best & Friedrich , who told a Fusion 2007 gathering that ...
... deal that will bring asset-tracking solutions to healthcare and ... a joint sales and marketing agreement with PanGo ... systems, technology, and services to buildings - including more ... the agreement will expand its wireless capabilities and provide ...
Cached Biology Technology:Fusion 2007: CA chief says IT complexity raises risk 2Fusion 2007: CA chief says IT complexity raises risk 3Fusion 2007: In e-legalities, CIOs and lawyers combine to provide business value 2Fusion 2007: In e-legalities, CIOs and lawyers combine to provide business value 3
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... N.C. , March 12, 2015 The ... at Brenner Children,s Hospital, part of Wake Forest Baptist ... outreach initiative for the 2015 ACC Men,s Basketball Tournament. ... pictures with them and getting their autographs. ... Forest Baptist. It is the only children,s hospital in ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... landmark genetic study has identified multiple genes linked to ... disease that affects an estimated 1.4 million Americans. ... brain and blood and occurs in about 31 out ... likely than men to develop the condition, which is ...
... from the January issue of Mayo Clinic Proceedings include ... workplace drug screening and the safety and effectiveness of ... Examine the Effect of Antioxidant Supplements on Cancer ... cancer and deaths related to cancer? Thats a question ...
... The National Academy of Sciences, Sackler Colloquium series ... These networks represent the genomic program for ... cell types. The meeting will focus on ... early embryonic development; gene networks later developmental processes; ...
Cached Biology News:Steps toward Stopping Autoimmune Disease 2Mayo Clinic Proceedings January tip sheet 2Mayo Clinic Proceedings January tip sheet 3
...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Supplemental reagent for annexin V assay....
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Biology Products: